Toleranzia AB - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 21 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Toleranzia AB - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Toleranzia AB - Product Pipeline Review - 2015', provides an overview of the Toleranzia AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Toleranzia AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Toleranzia AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Toleranzia AB's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Toleranzia AB's pipeline products

Reasons to Buy

- Evaluate Toleranzia AB's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Toleranzia AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Toleranzia AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Toleranzia AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Toleranzia AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Toleranzia AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Toleranzia AB Snapshot 4
Toleranzia AB Overview 4
Key Information 4
Key Facts 4
Toleranzia AB - Research and Development Overview 5
Key Therapeutic Areas 5
Toleranzia AB - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Toleranzia AB - Pipeline Products Glance 9
Toleranzia AB - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Toleranzia AB - Drug Profiles 10
Recombinant Protein for Allergy 10
Product Description 10
Mechanism of Action 10
R&D Progress 10
Recombinant Protein for Autoimmune Orphan Indications 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
Recombinant Protein for Multiple Sclerosis 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Recombinant Protein for Myasthenia Gravis 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Recombinant Protein for Rheumatoid Arthritis 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Recombinant Protein for Sjogren's Syndrome 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Recombinant Protein for Type 1 Diabetes 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Toleranzia AB - Pipeline Analysis 17
Toleranzia AB - Pipeline Products by Route of Administration 17
Toleranzia AB - Pipeline Products by Molecule Type 18
Toleranzia AB - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 20
Disclaimer 21

List of Tables

Toleranzia AB, Key Information 4
Toleranzia AB, Key Facts 4
Toleranzia AB - Pipeline by Indication, 2015 6
Toleranzia AB - Pipeline by Stage of Development, 2015 7
Toleranzia AB - Monotherapy Products in Pipeline, 2015 8
Toleranzia AB - Preclinical, 2015 9
Toleranzia AB - Pipeline by Route of Administration, 2015 17
Toleranzia AB - Pipeline by Molecule Type, 2015 18